Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC(tm)) technology for clinical diagnostics and scientific discovery, today announced new data highlighting the Company's ultrasensitive Erenna(r) Immunoassay System in the detection of cardiac troponin-I (cTnI). Two studies utilized the Erenna System to measure previously undetectable levels of cTnI in order to assess cardiovascular disease risk in rheumatoid arthritis (RA) and heart failure (HF) patients. The data were presented at the American Heart Association Scientific Sessions in Dallas, Texas.

Researchers reported Nov. 19 at the American Heart Association scientific session in Dallas that at three months 85 percent of patients with nonvalvular atrial fibrillation treated with rivaroxaban had continued to take the anticoagulant compared with 76 percent of patients on warfarin.

Despite an FDA warning that statins may be associated with cognitive deficits, a review published online Nov. 18 in Annals of Internal Medicine found no definitive evidence of a link between the cholesterol-management drugs and cognitive impairment.

Using vascular closure devices during PCI may be safer than manual closure, according to a study published online Nov. 18 in Annals of Internal Medicine. The devices were associated with fewer vascular complications and a reduced need for transfusions in patients undergoing transfemoral PCI.

Using genetic information to dose warfarin did not lead to better control of therapeutic levels, a study published online Nov. 19 in The New England Journal of Medicine found. The findings were simultaneously presented at the American Heart Association scientific session in Dallas.

Edoxaban may be as effective as warfarin in preventing strokes or systemic embolism and may also cause less bleeding and cardiovascular death, according to a study published online Nov. 19 in The New England Journal of Medicine and presented simultaneously at the American Heart Association scientific session in Dallas.

Varespladib significantly increased heart attack risk in patients with acute coronary syndrome (ACS) in a trial that terminated early due to futility and potential harm. The study findings were published online Nov. 18 in JAMA and presented simultaneously at the American Heart Association’s scientific session.

Patients with acute heart failure and kidney impairment do not benefit from either low-dose dopamine or low-dose nesiritide, according to a study published online Nov. 18 in JAMA and presented simultaneously at the American Heart Association’s scientific session in Dallas.